Our Business
Providing breakthrough treatments
for patients around the world
From mental health conditions to neurological disorders
In the central nervous system (CNS) field, building on the success of our globally recognized antipsychotic drug ABILIFY, in 2013 we launched ABILIFY Maintena, a once-monthly, extended-release antipsychotic injection, in the U.S. and it is now sold in over 50 countries and regions.
REXULTI, a new antipsychotic drug, was approved in the U.S. for the adjunctive treatment of major depressive disorder and the indication of schizophrenia and it is currently sold in approximately 60 countries and regions, including Japan. In 2023, it was approved by the U.S. FDA for the first time in the United States for the treatment of agitation in Alzheimer's-type dementia.
Otsuka's therapeutic drugs around the world
In the field of oncology, Busulfex, a conditioning agent prior to bone marrow transplantation in blood cancer, is now available in over 50 countries through Otsuka Pharmaceutical and its partners. It has become a standard treatment replacing radiotherapy within the bone marrow transplantation regimen.
Otsuka also signed an agreement with ARIAD Pharmaceuticals* to commercialize ARIAD's treatment for resistant and intolerant chronic myeloid leukemia in ten Asian countries and regions including Japan, and to fund future clinical trials in those countries. Sales in Japan began in 2016.
- *Acquired by Takeda in 2017
In the cardiovascular field, the vasopressin V2 receptor antagonist Samsca (generic name is tolvaptan) is an aquaretic with a novel mechanism of action that promotes excretion from the body of water only without affecting the excretion of electrolytes. It was launched in Europe and the U.S. in 2009 for hyponatremia, and later in Japan for edema due to heart failure and liver cirrhosis. In 2014, the world's first approval of a treatment for autosomal dominant polycystic kidney disease (ADPKD), an intractable disease with no treatments until now, was obtained for Samsca in Japan. Outside of Japan, it is sold under the global product names JINARC / JYNARQUE. Samsca / JINARC / JYNARQUE is now available in over 40 countries. In 2022, SAMTASU was launched as a prodrug of oral tolvaptan (generic name is tolvaptan sodium phosphate).
In the field of ophthalmology several drugs are available, including the dry-eye treatment Mucosta ophthalmic suspension and the antiglaucoma and anti-intraocular hypertension drugs Mikelan LA, and Mikeluna combination ophthalmic solution.
In the field of dermatology, Moizerto was launched in 2022 as the first topical PDE4 inhibitor approved in Japan for the treatment of atopic dermatitis.
(As of August 2024)
